68Ga-PSMA and 11C-Choline comparison using a tri-modality PET/CT-MRI (3.0 T) system with a dedicated shuttle

被引：21
作者：
Alonso O. [1 ,2 ]
dos Santos G. [1 ,2 ]
García Fontes M. [1 ]
Balter H. [1 ]
Engler H. [1 ]
机构：
[1] Uruguayan Centre of Molecular Imaging (CUDIM), Av. Ricaldoni 2010, Montevideo
[2] Nuclear Medicine and Molecular Imaging Centre, Hospital de Clínicas, Universidad de la República, Av. Italia S/N, Montevideo
来源：
European Journal of Hybrid Imaging | / 2卷 / 1期
关键词：
!sup]11[!/sup]C-Choline; !sup]68[!/sup]Ga-PSMA; Biochemical recurrence; PET/CT; PET/MRI; Prostate cancer;
D O I：
10.1186/s41824-018-0027-1
中图分类号：
学科分类号：
摘要：
Background: The aim of this study was to prospectively compare the detection rate of 68Ga-PSMA versus 11C-Choline in men with prostate cancer with biochemical recurrence and to demonstrate the added value of a tri-modality PET/CT-MRI system. Methods: We analysed 36 patients who underwent both 11C-Choline PET/CT and 68Ga-PSMA PET/CT scanning within a time window of 1-2 weeks. Additionally, for the 68Ga-PSMA scan, we used a PET/CT-MRI (3.0 T) system with a dedicated shuttle, acquiring MRI images of the pelvis. Results: Both scans were positive in 18 patients (50%) and negative in 8 patients (22%). Nine patients were positive with 68Ga-PSMA alone (25%) and one with 11C-Choline only (3%). The median detected lesion per patient was 2 for 68Ga-PSMA (range 0-93) and 1 for 11C-Choline (range 0-57). Tumour to background ratios in all concordant lesions (n = 96) were higher for 68Ga-PSMA than for 11C-Choline (110.3 ± 107.8 and 27.5 ± 17.1, mean ± S.D., for each tracer, respectively P = 0.0001). The number of detected lesions per patient was higher for 11C-Choline in those with PSA ≥ 3.3 ng/mL, while the number of detected lesions was independent of PSA levels for 68Ga-PSMA using the same PSA cut-off value. Metastatic pelvic lesions were found in 25 patients (69%) with 68Ga-PSMA PET/CT, in 18 (50%) with 11C-Choline PET/CT and in 21 (58%) with MRI (3.0 T). MRI was very useful in detecting recurrence in cases classified as indeterminate by means of PET/CT alone at prostate bed. Conclusions: In patients with prostate cancer with biochemical recurrence 68Ga-PSMA detected more lesions per patient than 11C-Choline, regardless of PSA levels. PET/CT-MRI (3.0 T) system is a feasible imaging modality that potentially adds useful relevant information with increased accuracy of diagnosis. © 2018, The Author(s).
引用
收藏
相关论文
共 55 条
[1]  
Afshar-Oromieh A., Haberkorn U., Eder M., Eisenhut M., Zechmann C., [68Ga]gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH, Eur J Nucl Med Mol Imaging, 39, pp. 1085-1086, (2012)
[2]  
Afshar-Oromieh A., Haberkorn U., Schlemmer H.P., Et al., Comparison of PET/CT and PET/MR hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience, Eur J Nucl Med Mol Imaging, 41, pp. 887-897, (2014)
[3]  
Afshar-Oromieh A., Holland-Letz T., Giesel F.L., Et al., Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients, Eur J Nucl Med Mol Imaging, 44, 10, (2017)
[4]  
Afshar-Oromieh A., Malcher A., Eder M., Eisenhut M., Linhart H.G., Hadaschik B.A., Et al., PET imaging with a [(68)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions, Eur J Nucl Med Mol Imaging, 40, pp. 486-495, (2013)
[5]  
Afshar-Oromieh A., Zechmann C.M., Malcher A., Et al., Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 41, pp. 11-20, (2014)
[6]  
Alonso O., dos Santos G., Garcia-Fontes M., Engler H., Prospective comparison of 11C-Choline versus 68Ga-PSMA using a tri-modality PET/CT-MR system for the diagnosis of prostate cancer patients with biochemical recurrence (abstract), J Nucl Med, 57, (2016)
[7]  
Bander N.H., Technology insight: monoclonal antibody imaging of prostate cancer, Nat Clin Pract Urol, 3, pp. 216-225, (2006)
[8]  
Beauregard J.M., Williams S.G., Degrado T.R., Roselt P., Hicks R.J., Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer, J Med Imaging Radiat Oncol, 54, pp. 325-332, (2010)
[9]  
Castellucci P., Fuccio C., Nanni C., Santi I., Rizzello A., Lodi F., Et al., Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prosta-tectomy, J Nucl Med, 50, pp. 1394-1400, (2009)
[10]  
Castellucci P., Fuccio C., Rubello D., Schiavina R., Santi I., Nanni C., Et al., Is there a role for (11)C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase < 1.5 ng/mL?, Eur J Nucl Med Mol Imaging, 38, pp. 55-63, (2011)
123456